DAWN

JW MARRIOTT TRANSPORTS MINDFULNESS TO ST. MAARTEN WITH THE OPENING OF JW MARRIOTT ST. MAARTEN BEACH RESORT & SPA

Retrieved on: 
Thursday, March 7, 2024
Lunch, Citrus, Flower, Marriott International, Seafood, Atlantic Ocean, Artifact, Mindfulness, Bok choy, DAWN, Carambola, Hotel

DAWN BEACH, St. Maarten, March 7, 2024 /PRNewswire/ -- JW Marriott, part of Marriott Bonvoy's portfolio of over 30 extraordinary hotel brands, today announces the opening of the first Marriott International luxury hotel in St. Maarten: JW Marriott St. Maarten Beach Resort & Spa. Nestled in a tropical haven exuding multicultural charm, JW Marriott St. Maarten Beach Resort & Spa embodies the brand's mindful ethos, offering travelers an enriching Caribbean retreat that nourishes the mind, body, and spirit.

Key Points: 
  • Nestled in a tropical haven exuding multicultural charm, JW Marriott St. Maarten Beach Resort & Spa embodies the brand's mindful ethos, offering travelers an enriching Caribbean retreat that nourishes the mind, body, and spirit.
  • "JW Marriott St. Maarten Beach Resort & Spa marks our debut in this striking corner of the Caribbean, not only punctuating our incredible growth in the region, but also strengthening our global presence," said Bruce Rohr, Vice President and Global Brand Leader, JW Marriott.
  • Upon arrival at JW Marriott St. Maarten Beach Resort & Spa, guests are welcomed by a majestic two-story stone clad tower, crowned with an ornate steel dome that pays homage to the island's rich Dutch architectural heritage.
  • "JW Marriott offers guests a legacy of luxury hospitality matched with principles of mindfulness that are integral to today's traveler," said Todd Reichelt, General Manager, JW Marriott St. Maarten Beach Resort & Spa.

Net-Zero Transportation Enabled by CO2-Derived e-Fuels, Finds IDTechEx

Retrieved on: 
Wednesday, December 6, 2023
Carbon, Aviation, Pressure, Biomass, DAWN, Hydrogenation, Membrane, Plant, Metal, Hydrogen, EVS, Federal Aviation Regulations, CO2, History, Fossil, Methanol, Electrochemistry, Maersk, European, Mining, H2, Biofuel, PTL, DAC, ExxonMobil, Electricity, EV, Energy storage, Carbon Recycling International, CRI, Players, Gasoline, Renewable energy, Wood, Coal, Lithium

They offer carbon footprint reductions compared to their fossil fuel equivalents and are carbon neutral in some cases.

Key Points: 
  • They offer carbon footprint reductions compared to their fossil fuel equivalents and are carbon neutral in some cases.
  • For further information on sustainable fuels and utilizing CO2 as a raw material, please refer to the IDTechEx sustainability reports portfolio .
  • Point source capture technologies, including liquid solvents, solid adsorbents, and membranes, are commercially available and are forecasted by IDTechEx to exceed 1 Gtpa capture capacity by 2040.
  • More information on this synthesis can be found in the IDTechEx Carbon Dioxide Utilization 2022-2042: Technologies, Market Forecasts, and Players report.

Net-Zero Transportation Enabled by CO2-Derived e-Fuels, Finds IDTechEx

Retrieved on: 
Wednesday, December 6, 2023
Carbon, Aviation, Pressure, Biomass, DAWN, Hydrogenation, Membrane, Plant, Metal, Hydrogen, EVS, Federal Aviation Regulations, CO2, History, Fossil, Methanol, Electrochemistry, Maersk, European, Mining, H2, Biofuel, PTL, DAC, ExxonMobil, Electricity, EV, Energy storage, Carbon Recycling International, CRI, Players, Gasoline, Renewable energy, Wood, Coal, Lithium

They offer carbon footprint reductions compared to their fossil fuel equivalents and are carbon neutral in some cases.

Key Points: 
  • They offer carbon footprint reductions compared to their fossil fuel equivalents and are carbon neutral in some cases.
  • For further information on sustainable fuels and utilizing CO2 as a raw material, please refer to the IDTechEx sustainability reports portfolio .
  • Point source capture technologies, including liquid solvents, solid adsorbents, and membranes, are commercially available and are forecasted by IDTechEx to exceed 1 Gtpa capture capacity by 2040.
  • More information on this synthesis can be found in the IDTechEx Carbon Dioxide Utilization 2022-2042: Technologies, Market Forecasts, and Players report.

Rare Disease Week 2023: Exploring Accessibility in Rare Disease Clinical Research, 4-Day Webinar Series Hosted by Xtalks

Retrieved on: 
Tuesday, March 7, 2023
Horizon Therapeutics, FSR, Health care, ICON PLC, Veronica, Partner (business rank), CHES, In-product communication, MD, MBA, Sarcoidosis, Senior, Janssen Pharmaceuticals, Disease, Enrollment, Decentralized Trials & Research Alliance, Bristol Myers Squibb, Entrepreneurship, College, Research, AVP Research Foundation, MPH, Rutgers University, Commercialization, Chairperson, IBD, Doctor of Philosophy, DCTS, Host, Patient advocacy, Gallaudet University, DAWN, Real Time Information Group, ICON, DEI, Bachelor of Science, Public affairs, Zwanzig projection operator, Nursing, Pharmaceutical industry, Birth control, Management, Honours degree, The Swift Home Service Club, Neuromuscular junction

TORONTO, March 7, 2023 /PRNewswire-PRWeb/ -- Each panel in this 4-day webinar series, whether watched individually or in totality with the other panels, will provide insights into the value of accessibility in rare disease clinical research and how sponsors, patient advocates, researchers and regulators might move from discussion to action.

Key Points: 
  • In this free webinar series, learn about myriad types of accessibility considerations for rare disease clinical research.
  • Attendees will learn how accessibility considerations fit into diversity, equity, and inclusion (DEI) plans.
  • The featured speakers will discuss best practices in accessible clinical trial design and implementation.
  • Panel 1: Is Disability Part of Your DEI Planning and Engagement in Rare Disease?

Ecolab Earns Top Score of 100; Recognized as a Best Place to Work for Disability Inclusion

Retrieved on: 
Wednesday, July 20, 2022
Other Health, Professional Services, Sustainability, Technology, Hospitals, Environment, DEI (Diversity, Equity and Inclusion), Green Technology, Chemicals, Plastics, Food Tech, Manufacturing, Health, People, Goal, Association, AAPD, Food, Water, Human resources, DAWN, Disability, Culture, Minister of Employment, Workforce Development and Disability Inclusion, American Association, Inclusion, Organization, Equity, Health, ECL, Growth, Food safety, American Association of People with Disabilities, Hygiene, Insurance, Health insurance, Ecolab

For the first time, Ecolab Inc., the global leader in water, hygiene and infection prevention solutions and services that protect people, planet and business health, has received a top score of 100 on the Disability Equality Index and been recognized as a Best Place to Work for Disability Inclusion.

Key Points: 
  • For the first time, Ecolab Inc., the global leader in water, hygiene and infection prevention solutions and services that protect people, planet and business health, has received a top score of 100 on the Disability Equality Index and been recognized as a Best Place to Work for Disability Inclusion.
  • A joint initiative of the American Association of People with Disabilities (AAPD), the nations largest disability rights organization, and Disability:IN, the global business disability inclusion network, to collectively advance the inclusion of people with disabilities.
  • The organizations are complimentary and bring unique strengths that make the project relevant and credible to corporations and the disability community.
  • The tool was developed by the DEI Advisory Committee, a diverse group of business leaders, policy experts and disability advocates.

Bristol Myers Squibb Launches Disability Diversity in Clinical Trials (DDiCT) Initiative to Improve Healthcare Outcomes for People with Disabilities

Retrieved on: 
Wednesday, July 20, 2022
DEI (Diversity, Equity and Inclusion), Pharmaceutical, Human Resources, Health, Social Services, Professional Services, Clinical Trials, Other Health, People, American Medical Association, JAMA, III, IV, Medicaid, Physical, DAWN, BMY, Hotel manager, Twitter, Instagram, Journal of Global Drug Policy and Practice, Disability, NYSE, Research, Workforce, Health, Disability in Canada, Epidemiology, Bristol Myers Squibb, Clinical trial, YouTube, Journal, Patient, LinkedIn, Health equity, Medicine, Pharmaceutical industry, Facebook, Medicare

Bristol Myers Squibb (NYSE:BMY) today announced, in collaboration with Disability Solutions, a U.S.- based non-profit organization that supports companies globally to achieve true disability inclusion, the launch of the Disability Diversity in Clinical Trials (DDiCT) initiative.

Key Points: 
  • Bristol Myers Squibb (NYSE:BMY) today announced, in collaboration with Disability Solutions, a U.S.- based non-profit organization that supports companies globally to achieve true disability inclusion, the launch of the Disability Diversity in Clinical Trials (DDiCT) initiative.
  • This new initiative aligns with Bristol Myers Squibbs broader inclusion and diversity health equity commitments to address health disparities, clinical trial diversity, supplier diversity, employee giving, and workforce representation between 2020 and 2025.
  • "Through this work, Bristol Myers Squibb can set the standard and stage for access to life-changing and life-saving medicines for people with disabilities, said Samit Hirawat, M.D., executive vice president and chief medical officer, Global Drug Development, Bristol Myers Squibb.
  • For press inquiries related to Disability Solutions or Ability Beyond, please contact Julie Sowash, Executive Director of Disability Solutions at [email protected] .

Global Cancer Biomarkers Market to Surpass US$ 63,377.8 Million by 2030 - Coherent Market Insights

Retrieved on: 
Monday, July 4, 2022
Melanoma, Death, Patient, Primary central nervous system lymphoma, Pembrolizumab, Research, Breast cancer, Merck, DAWN, Biomarker, PerkinElmer, Growth, CNS, Cancer, Blood, Urine, Analysis, Company, Fluid mechanics, US, Thermo Fisher Scientific, EHA, Prevalence, World, Therapy, National Cancer Institute, CAGR, Nivolumab, University, World Health Organization, Ipilimumab, National, QIAGEN, Medical imaging, Pharmaceutical industry

SEATTLE, July 4, 2022 /PRNewswire/ -- According to Coherent Market Insights, the Global Cancer Biomarkers Market is estimated to be valued at US$ 21,643.9 million in 2022 and is expected to exhibit a CAGR of 14.4% during the forecast period (2022-2030).

Key Points: 
  • SEATTLE, July 4, 2022 /PRNewswire/ -- According to Coherent Market Insights, the Global Cancer Biomarkers Market is estimated to be valued at US$ 21,643.9 million in 2022 and is expected to exhibit a CAGR of 14.4% during the forecast period (2022-2030).
  • Key Trends and Analysis of the Global Cancer Biomarkers Market:
    Major players operating in market are focusing on carrying out research and development activities for developing biomarkers for early detection of cancer.
  • Global cancer biomarkers market is expected to exhibit a CAGR of 14.4% during the forecast period due to the increasing prevalence of cancer.
  • Market players are focusing on carrying out research and developments activities for developing protein biomarkers for the detection of cancer, which is expected to drive market growth.

Mark Ingram Bride Announces the Launch of LGD By Mark Ingram

Retrieved on: 
Thursday, June 23, 2022
TerraPass, DAWN, Industry, LGD, Eye, Gold, Multimedia, Family, Collection, Carbon, Jewellery

NEW YORK, June 23, 2022 /PRNewswire/ -- Mark Ingram Bride announces its launch of LGD By Mark Ingram, the atelier's first in house jewelry line.

Key Points: 
  • NEW YORK, June 23, 2022 /PRNewswire/ -- Mark Ingram Bride announces its launch of LGD By Mark Ingram, the atelier's first in house jewelry line.
  • Designer, industry leader, and Mark Ingram Atelier founder- Mark Ingram steps into the jewelry space and the sustainability space announcing to the industry that he has and will continue to push boundaries in the bridal space.
  • LGD By Mark Ingram's entire debut collection is available now on lgd-bymarkingram.com and in store at The Mark Ingram Atelier, 110 E 55th St #8, New York, NY 10022.
  • For more information on LGD by Mark Ingram, please contact [email protected] .

Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022

Retrieved on: 
Tuesday, June 7, 2022
DREAM, Woman, National Medical Products Administration, GK, Company, FPG, GKA, Observation, DAWN, Research, Jak Airport, ADA, CEO, Education, Disease, World Diabetes Day, Type 2 diabetes, Insulin resistance, Patient, Glycated hemoglobin, Insulin, Metformin, Trial of the century, Chinese, Glucokinase, Type 2, Association, American Diabetes Association, Department, Public health, Hospital, NDA, Blood, Homeostasis, Drug development, Chinese University of Hong Kong, Attention, Glucose clamp technique, China-Japan Friendship Hospital, WIN, SEED, Pharmaceutical industry, Epidemiology, Diabetes, T2D

A post-hoc analysis that involved two Phase III clinical trials of dorzagliatin indicated that dorzagliatin can significantly improve early phase insulin secretion and glucose sensitivity of patients of Type 2 diabetes (T2D).

Key Points: 
  • A post-hoc analysis that involved two Phase III clinical trials of dorzagliatin indicated that dorzagliatin can significantly improve early phase insulin secretion and glucose sensitivity of patients of Type 2 diabetes (T2D).
  • Another clinical study called SENSITIZE also provided clinical scientific data of dorzagliatin in improving insulin secretion and glucose sensitivity.
  • The study results, using glucose clamp technique, showed that dorzagliatin can significantly improve second phase insulin secretion and glucose sensitivity in GCK-MODY patients and can significantly improve basal insulin secretion rates in patients with recent onset T2D.
  • Targeting the glucose sensor glucokinase, dorzagliatin, a novel oral diabetes drug restoring glucose sensitivity in T2D patients, has completed SEED and DAWN registration trials, and filed NDA in China.

InterVenn Biosciences Announces New Data Validating the Clinical Performance of DAWN™ IO Melanoma as a Novel Liquid Biopsy Test to Improve Assessment of Benefit to Cancer Patients

Retrieved on: 
Thursday, June 2, 2022
Oncology, Health, Medical Devices, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Sugar, Biomarker, Immunotherapy, ICIS, Biology, DAWN, Liquid biopsy, MGH, Melanoma, Progression-free survival, CEO, Cancer, Massachusetts General Hospital, List of life sciences, Neoplasm, Physician, Pembrolizumab, Glycoprotein, Patient, Oncology, Perspectivism, Nivolumab, Clinical trial, Glycosylation, Health, Ipilimumab, Protein, Medical imaging, Pharmaceutical industry

InterVenn conducted the validation study of the new DAWN IO Melanoma test in collaboration with Mass General Hospital (MGH), on a cohort of 205 advanced melanoma patients.

Key Points: 
  • InterVenn conducted the validation study of the new DAWN IO Melanoma test in collaboration with Mass General Hospital (MGH), on a cohort of 205 advanced melanoma patients.
  • DAWN IO Melanoma is the first in a series of liquid biopsy-based assays that InterVenn plans to develop under the DAWN IO brand to address a variety of cancers.
  • Built to meet clinical requirements, DAWN IO Melanoma interrogates the blood glycoproteome at an unprecedented speed and scale.
  • The DAWN IO Melanoma test was developed, and its performance characteristics were determined by InterVenn.